Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, a Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases
Preclinical data establish MRT-6160’s ability to potently and selectively degrade VAV1 and inhibit disease progression…